<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ911223-0152</DOCNO><DOCID>911223-0152.</DOCID><HL>   Cytogen's Diagnostic Agent</HL><DATE>12/23/91</DATE><SO>WALL STREET JOURNAL (J), PAGE B5</SO><CO>   CYTO</CO><MS>TECHNOLOGY (TEC)</MS><IN>BIOTECHNOLOGY (BTC)MEDICAL andamp; BIOTECHNOLOGY, GENETIC RESEARCH, PROSTHETICS (MTC)</IN><GV>FOOD AND DRUG ADMINISTRATION (FDA)</GV><RE>NEW JERSEY (NJ)NORTH AMERICA (NME)UNITED STATES (US)</RE><LP>   PRINCETON, N.J. -- Cytogen Corp. said the Food and DrugAdministration announced it will review next month thecompany's product license application for OncoScint OV103, animaging agent for diagnosing certain kinds of cancer.   The application is being reviewed at a meeting of an FDAcommittee on Jan. 16, the biotechnology concern said.</LP><TEXT/></DOC>